Plaque Formation Assay for Human Parainfluenza Virus Type 1

• Fukushima Keijo

  Department of Biochemistry, School of Pharmaceutical Sciences and Global COE Program for Innovation in Human Health Sciences, University of Shizuoka

• Takahashi Tadanobu

  Department of Biochemistry, School of Pharmaceutical Sciences and Global COE Program for Innovation in Human Health Sciences, University of Shizuoka

• Takaguchi Masahiro

  Department of Biochemistry, School of Pharmaceutical Sciences and Global COE Program for Innovation in Human Health Sciences, University of Shizuoka

• Ueyama Hiroo

  Department of Biochemistry, School of Pharmaceutical Sciences and Global COE Program for Innovation in Human Health Sciences, University of Shizuoka

• Ito Seigo

  Department of Biochemistry, School of Pharmaceutical Sciences and Global COE Program for Innovation in Human Health Sciences, University of Shizuoka

• Kurebayashi Yuuki

  Department of Biochemistry, School of Pharmaceutical Sciences and Global COE Program for Innovation in Human Health Sciences, University of Shizuoka

• Kawanishi Tomohiro

  Department of Biochemistry, School of Pharmaceutical Sciences and Global COE Program for Innovation in Human Health Sciences, University of Shizuoka

• McKimm-Breschkin Jennifer Lois

  CSIRO Molecular and Health Technologies

• Takimoto Toru

  Department of Microbiology and Immunology, University of Rochester Medical Center

• Minami Akira

  Department of Biochemistry, School of Pharmaceutical Sciences and Global COE Program for Innovation in Human Health Sciences, University of Shizuoka

• Suzuki Takashi

  Department of Biochemistry, School of Pharmaceutical Sciences and Global COE Program for Innovation in Human Health Sciences, University of Shizuoka

抄録

Human parainfluenza virus type 1 (hPIV1) generally does not show visible plaques in common cell lines, including Lewis lung carcinoma-monkey kidney (LLC-MK₂) cells, by plaque formation assays for human parainfluenza virus type 3 (hPIV3) and Sendai virus. In several conditions of the plaque formation assay, complete elimination of serum proteins in the overlay medium was necessary for visualization of hPIV1-induced plaque formation in LLC-MK₂ cells. We developed a plaque formation assay for hPIV1 isolation and titration in LLC-MK₂ cells using an initial overlay medium of bovine serum albumin-free Eagle's minimum essential medium containing agarose and acetylated trypsin for 4—6 d followed by a second overlay staining medium containing agarose and neutral red. The assay allowed both laboratory and clinical hPIV1 strains to form large plaques. The plaque reduction assay was also performed with rabbit anti-hPIV1 antibody as a general evaluation model of viral inhibitors to decrease both the plaque number and size. The results indicate that the plaque formation assay is useful for hPIV1 isolation, titration, evaluation of antiviral reagents and epidemiologic research.

収録刊行物

• Ｂｉｏｌｏｇｉｃａｌ　＆　Ｐｈａｒｍａｃｅｕｔｉｃａｌ　Ｂｕｌｌｅｔｉｎ

  Ｂｉｏｌｏｇｉｃａｌ　＆　Ｐｈａｒｍａｃｅｕｔｉｃａｌ　Ｂｕｌｌｅｔｉｎ 34 (7), 996-1000, 2011

  公益社団法人 日本薬学会

キーワード

• human parainfluenza virus type 1
• plaque assay
• isolation
• Lewis lung carcinoma-monkey kidney cell
• antiviral reagent

詳細情報

• CRID: 1390001204632742016
• NII論文ID: 130000738086
• NII書誌ID: AA10885497
• DOI: 10.1248/bpb.34.996
• ISSN: 13475215
• ISSN: 09186158
• NDL書誌ID: 11132432
• Web Site: https://ndlsearch.ndl.go.jp/books/R000000004-I11132432
• Web Site: http://www.jstage.jst.go.jp/article/bpb/34/7/34_7_996/_pdf
• Web Site: https://search.jamas.or.jp/link/ui/2012151803
• 本文言語コード: en
• データソース種別:
  • JaLC
  • NDL
  • Crossref
  • CiNii Articles
  • KAKEN
• 抄録ライセンスフラグ: 使用不可